BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/31/2024 8:01:10 AM | Browse: 91 | Download: 471
 |
Received |
|
2024-09-02 12:20 |
|
Peer-Review Started |
|
2024-09-02 12:20 |
|
First Decision by Editorial Office Director |
|
2024-09-17 05:58 |
|
Return for Revision |
|
2024-09-17 05:58 |
|
Revised |
|
2024-09-26 17:43 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-10-18 01:32 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-10-20 10:22 |
|
Articles in Press |
|
2024-10-20 10:22 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-10-28 06:00 |
|
Publish the Manuscript Online |
|
2024-10-31 08:01 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Letter to the Editor |
| Article Title |
SGLT2 inhibitors in the prevention of diabetic cardiomyopathy: Targeting the silent threat
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Panayotis K Vlachakis, Panagiotis Theofilis and Dimitris Tousoulis |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Dimitris Tousoulis, PhD, Professor, Department of 1st Cardiology, Athens Medical School, National and Kapodistrian University of Athens, Mantouvalou 3, Athens 11527, Greece. drtousoulis@hotmail.com |
| Key Words |
Sodium-dependent glucose transporter 2 inhibitor; Diabetes mellitus; Heart failure; Pathophysiology; Inflammation; Oxidative stress |
| Core Tip |
Sodium-dependent glucose transporter 2 inhibitors show promise in improving cardiac function and reducing cardiovascular risks in patients with type 2 diabetes mellitus and asymptomatic heart failure (HF). Early intervention with these drugs could be key in preventing the progression of diabetic cardiomyopathy, making them an important consideration in managing high-risk diabetic patients before symptoms of HF emerge. |
| Publish Date |
2024-10-31 08:01 |
| Citation |
Vlachakis PK, Theofilis P, Tousoulis D. SGLT2 inhibitors in the prevention of diabetic cardiomyopathy: Targeting the silent threat. World J Cardiol 2024; 16(11): 669-672 |
| URL |
https://www.wjgnet.com/1949-8462/full/v16/i11/669.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v16.i11.669 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
